Nonlinear EEG Feature Analysis for Epilepsy Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for diagnosing epilepsy are time-consuming, expensive, and rely on observing seizures, which are unpredictable and difficult to record, leading to delayed diagnosis and treatment.

Innovation Solution

The use of multiscale algorithms, such as wavelet transforms and recurrence quantitative analysis, to identify nonlinear features in EEG data as biomarkers for epilepsy, allowing for the diagnosis of epilepsy without requiring the occurrence of seizures.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional diagnosis methods relying on seizure observation are used, then diagnosis accuracy can be achieved, but diagnosis time and cost increase significantly

Engineering Contradiction:
Improvediagnosis accuracyVSAvoiddiagnosis time
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The patent applies preliminary action by analyzing nonlinear features of EEG signals to detect epileptogenicity before seizures occur. The system identifies biomarkers in interictal (seizure-free) EEG recordings, enabling early diagnosis without waiting for unpredictable seizure events. This transforms the diagnostic approach from reactive (observing seizures) to proactive (detecting predisposition), significantly reducing diagnosis time while maintaining accuracy.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If multiple clinical visits and work-up studies are conducted, then diagnosis reliability improves, but diagnostic cost increases

Engineering Contradiction:
Improvediagnosis reliabilityVSAvoiddiagnostic cost
Core Design Contradiction:
ReliabilityVSLoss of energy

Solution Approach 1:

The patent extracts the essential diagnostic information from EEG signals by identifying specific nonlinear features (entropy, fractal dimension, correlation dimension) that characterize epileptogenicity. This extraction process isolates the key biomarkers needed for reliable diagnosis, eliminating the need for multiple redundant clinical visits and expensive work-up studies. The system achieves high diagnostic reliability by focusing on these extracted features rather than requiring comprehensive traditional evaluation.

Inventive Principle:
Principle #2Taking out (Extraction)

3Measurement precision

If seizure occurrence is used as a surrogate marker, then epilepsy diagnosis can be made, but early detection capability is lost

Engineering Contradiction:
Improvediagnosis capabilityVSAvoiddetection delay
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The system performs preliminary detection of epileptogenicity by analyzing nonlinear EEG features during interictal periods, before seizures manifest. This allows clinicians to identify patients with epilepsy predisposition early in the diagnostic process, enabling timely intervention and treatment planning without waiting for seizure occurrences. The approach transforms seizures from diagnostic prerequisites to detectable outcomes of already-identified pathology.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS10278608B2Detection of epileptogenic brains with non-linear analysis of electromagnetic signals
Publication Date: 2019.05.07 CHILDRENS MEDICAL CENT CORP
  • US10278608B2 patent drawing
  • US10278608B2 patent drawing
  • US10278608B2 patent drawing

AI summary

Methods and apparatus for identifying and using at least one nonlinear feature determined from multiscale electroencephalography (EEG) data to evaluate an epileptogenicity level of a patient is described. A multiscale algorithm is applied to EEG data recorded from the patient to produce scaled EEG data. At least one nonlinear feature value for the received EEG data and/or the scaled EEG data is determined and the at least one nonlinear feature value is used, at least in part, to evaluate the epileptogenicity level of the patient.